All In Biotech

Drug Trial Radar · NCT07339839

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Prospective, Multi-center, Phase I/II Clinical Study

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Sep 30, 2027

Study completion Sep 30, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) of Glecirasib in combination with Ivonescimab in patients with previously untreated, KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥1%. The study includes a Phase I 3+3 dose-escalation stage followed by a Phase II Simon two-stage design to assess preliminary antitumor efficacy.

Conditions

  • NSCLC Stage IV
  • KRAS G12C

Interventions

  • GlecirasibDrug

    For Phase I Dose Escalation, Glecirasib includes 2 dose cohorts: 600 mg QD and 800 mg QD, respectively, to determine the Glecirasib PR2D dose for the Phase II study.

  • IvonescimabDrug

    Administered intravenously at 20 mg/kg, every 3 weeks (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated Dose (MTD)Time frame: 21 days after the first dose.
  2. Phase I: Incidence of Dose-Limiting Toxicities (DLTs)Time frame: 21 days after the first dose.
  3. Phase I: Recommended Phase 2 Dose (RP2D)Time frame: 21 days after the first dose.
  4. Phase II: Objective Response Rate (ORR)Time frame: Assessed up to 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.